Page 22 - Mbc Parade Coverage News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mbc parade coverage. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mbc Parade Coverage Today - Breaking & Trending Today

Kansas City Chiefs parade shooting advice for children

The biggest tip: Start with understanding ....

How To , Kansas City Chiefs , Kansas City ,

CAPItello-291 Trial: Evaluating Capivasertib Plus Fulvestrant in Patients With HR+, HER2- Advanced Breast Cancer

Laura Huppert, MD, and Yara Abdou, MD, discuss the CAPItello-291 trial which looked at the efficacy of capivasertib, a small molecule AKT inhibitor, in combination with fulvestrant for patients with estrogen receptor positive, HER2 negative advanced breast cancer who had progressed on prior endocrine therapy. ....

Yara Abdou , Laura Huppert , Emerging Therapies , Breast Cancer , Evaluating Capivasertib Plus Fulvestrant , Patients With , Metastatic Breast Cancer , Breast Cancer Treatments , Breast Cancer Therapies , Metastatic Breast Cancer Treatments ,

The EMERALD Trial: Elacestrant in Patients with HR+, HER2- Advanced Breast Cancer

The EMERALD study showed improved progression-free survival with elacestrant compared to standard endocrine therapy in patients with ESR1 mutations who progressed on prior AI and CDK4/6 inhibitors, with the greatest benefit in those having longer duration of response to first-line therapy. ....

Emerging Therapies , Breast Cancer , Metastatic Breast Cancer , Breast Cancer Treatments , Breast Cancer Therapies , Metastatic Breast Cancer Treatments ,

Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

Experts delve into practical aspects of using elacestrant in later-line treatment of patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer, including testing for ESR1 mutations, evaluating efficacy, and monitoring for toxicity. ....

Rena Callahan , William Gradishar , Mabel Mardones , Gregory Vidal , Peer Exchange , Oral Serd , Metastatic Breast Cancer , Therapeutic Advances , Panel Discussion , Her Positive , Her2 Negative , Selective Estrogen Receptor Degrader , Endocrine Therapy , Targeted Therapy , Treatment Developments , Medical Oncology , Breast Oncology , Breast Cancer , Clinical Guidelines , Fda Label , Nccn Guidelines , Esr1 Mutations , Treatment Resistance , Moral Therapy , Disease Progression , Patient Profiles ,

ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and discuss unmet needs in this patient population. They also describe options for mutation and resistance marker testing to guide treatment selection. ....

William Gradishar , Rena Callahan , Mabel Mardones , Gregory Vidal , Peer Exchange , Oral Serd , Metastatic Breast Cancer , Therapeutic Advances , Panel Discussion , Her Positive , Her2 Negative , Selective Estrogen Receptor Degrader , Endocrine Therapy , Targeted Therapy , Treatment Developments , Medical Oncology , Breast Oncology , Breast Cancer , Clinical Guidelines , Fda Label , Nccn Guidelines , Esr1 Mutations , Treatment Resistance , Moral Therapy , Disease Progression , Patient Profiles ,